UPDATE 1-Dassault Systemes in talks to buy drug trial software firm ArisGlobal, FT reports

Adds details

July 16 (Reuters) - French software maker Dassault Systemes DAST.PA is in talks to buy drug-trial software maker ArisGlobal from Nordic Capital for about $2 billion, the Financial Times reported on Thursday, citing people familiar with the matter.

  • The potential deal would extend Dassault Systemes' foray into software used in life sciences and would rank as its second-biggest acquisition after its $5.8 billion takeover of clinical trial software group Medidata Solutions in 2019, the report said.

  • A transaction between the two firms is not a foregone conclusion, and talks could still fall apart, FT said.

  • Reuters could not immediately verify the report.

  • In April, Dassault Systemes reported first-quarter revenue of 1.51 billion euros ($1.77 billion), in line with estimates.

  • Hit by a prolonged slowdown in the global auto industry, Dassault Systemes, which provides software to automakers, plane manufacturers and industrial firms, is increasingly tapping augmented AI and data centers to drive growth.

  • Dassault Systemes, ArisGlobal and Nordic Capital could not immediately be reached for comment.


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.